Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer

A. V. D'Amico, J. E. Tomaszewski, A. A. Renshaw, A. Wein, J. P. Richie, David Grignon, A. Zietman, D. Bostwick, R. Whittington, S. B. Malkowicz, D. Schultz, B. Silver, L. Henry, M. Hurwltz, I. Kaplan, C. J. Beard

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background and Purpose: The clinical utility of the percentage of positive prostate biopsies in predicting prostate specific antigen (PSA) outcome after radical prostatectomy (RP) or external-beam radiation therapy (EBRT) for men with PSA-detected or palpable prostate cancer is not established. Methods: A Cox regression multivariable analysis was used to determine whether percent-positive prostate biopsies provided clinically relevant information about PSA outcome after RP in 960 men, while accounting for the previously established risk groups based on the pretreatment PSA concentration biopsy Gleason score, and the 1992 American Joint Commission on Cancer clinical T stage. Results: In the intermediate-risk group, 80% of the patients (stage T(2b) or biopsy Gleason 7 or PSA 10-20 ng/mL) could be classified into either an 11% or an 86% 4-year PSA control cohort using the preoperative prostate biopsy data. These findings were validated using an independent surgical (N = 823) and radiation (N = 473) data set. Percent-positive prostate biopsies added clinically significant information regarding time to PSA failure after RP. Conclusions: The percentage of positive prostate biopsies should be considered in conjunction with the PSA level, biopsy Gleason score, and clinical T stage when counseling patients with newly diagnosed and clinically localized prostate cancer about PSA outcome after RP or EBRT.

Original languageEnglish (US)
JournalMolecular Urology
Volume4
Issue number3
StatePublished - 2000
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Prostate
Prostatic Neoplasms
Radiotherapy
Biopsy
Neoplasm Grading
Counseling
Joints
Regression Analysis
Radiation

ASJC Scopus subject areas

  • Urology

Cite this

Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. / D'Amico, A. V.; Tomaszewski, J. E.; Renshaw, A. A.; Wein, A.; Richie, J. P.; Grignon, David; Zietman, A.; Bostwick, D.; Whittington, R.; Malkowicz, S. B.; Schultz, D.; Silver, B.; Henry, L.; Hurwltz, M.; Kaplan, I.; Beard, C. J.

In: Molecular Urology, Vol. 4, No. 3, 2000.

Research output: Contribution to journalArticle

D'Amico, AV, Tomaszewski, JE, Renshaw, AA, Wein, A, Richie, JP, Grignon, D, Zietman, A, Bostwick, D, Whittington, R, Malkowicz, SB, Schultz, D, Silver, B, Henry, L, Hurwltz, M, Kaplan, I & Beard, CJ 2000, 'Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer', Molecular Urology, vol. 4, no. 3.
D'Amico, A. V. ; Tomaszewski, J. E. ; Renshaw, A. A. ; Wein, A. ; Richie, J. P. ; Grignon, David ; Zietman, A. ; Bostwick, D. ; Whittington, R. ; Malkowicz, S. B. ; Schultz, D. ; Silver, B. ; Henry, L. ; Hurwltz, M. ; Kaplan, I. ; Beard, C. J. / Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. In: Molecular Urology. 2000 ; Vol. 4, No. 3.
@article{29399f73a82f4106824c3e066f7cae89,
title = "Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer",
abstract = "Background and Purpose: The clinical utility of the percentage of positive prostate biopsies in predicting prostate specific antigen (PSA) outcome after radical prostatectomy (RP) or external-beam radiation therapy (EBRT) for men with PSA-detected or palpable prostate cancer is not established. Methods: A Cox regression multivariable analysis was used to determine whether percent-positive prostate biopsies provided clinically relevant information about PSA outcome after RP in 960 men, while accounting for the previously established risk groups based on the pretreatment PSA concentration biopsy Gleason score, and the 1992 American Joint Commission on Cancer clinical T stage. Results: In the intermediate-risk group, 80{\%} of the patients (stage T(2b) or biopsy Gleason 7 or PSA 10-20 ng/mL) could be classified into either an 11{\%} or an 86{\%} 4-year PSA control cohort using the preoperative prostate biopsy data. These findings were validated using an independent surgical (N = 823) and radiation (N = 473) data set. Percent-positive prostate biopsies added clinically significant information regarding time to PSA failure after RP. Conclusions: The percentage of positive prostate biopsies should be considered in conjunction with the PSA level, biopsy Gleason score, and clinical T stage when counseling patients with newly diagnosed and clinically localized prostate cancer about PSA outcome after RP or EBRT.",
author = "D'Amico, {A. V.} and Tomaszewski, {J. E.} and Renshaw, {A. A.} and A. Wein and Richie, {J. P.} and David Grignon and A. Zietman and D. Bostwick and R. Whittington and Malkowicz, {S. B.} and D. Schultz and B. Silver and L. Henry and M. Hurwltz and I. Kaplan and Beard, {C. J.}",
year = "2000",
language = "English (US)",
volume = "4",
journal = "Molecular Urology",
issn = "1091-5362",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer

AU - D'Amico, A. V.

AU - Tomaszewski, J. E.

AU - Renshaw, A. A.

AU - Wein, A.

AU - Richie, J. P.

AU - Grignon, David

AU - Zietman, A.

AU - Bostwick, D.

AU - Whittington, R.

AU - Malkowicz, S. B.

AU - Schultz, D.

AU - Silver, B.

AU - Henry, L.

AU - Hurwltz, M.

AU - Kaplan, I.

AU - Beard, C. J.

PY - 2000

Y1 - 2000

N2 - Background and Purpose: The clinical utility of the percentage of positive prostate biopsies in predicting prostate specific antigen (PSA) outcome after radical prostatectomy (RP) or external-beam radiation therapy (EBRT) for men with PSA-detected or palpable prostate cancer is not established. Methods: A Cox regression multivariable analysis was used to determine whether percent-positive prostate biopsies provided clinically relevant information about PSA outcome after RP in 960 men, while accounting for the previously established risk groups based on the pretreatment PSA concentration biopsy Gleason score, and the 1992 American Joint Commission on Cancer clinical T stage. Results: In the intermediate-risk group, 80% of the patients (stage T(2b) or biopsy Gleason 7 or PSA 10-20 ng/mL) could be classified into either an 11% or an 86% 4-year PSA control cohort using the preoperative prostate biopsy data. These findings were validated using an independent surgical (N = 823) and radiation (N = 473) data set. Percent-positive prostate biopsies added clinically significant information regarding time to PSA failure after RP. Conclusions: The percentage of positive prostate biopsies should be considered in conjunction with the PSA level, biopsy Gleason score, and clinical T stage when counseling patients with newly diagnosed and clinically localized prostate cancer about PSA outcome after RP or EBRT.

AB - Background and Purpose: The clinical utility of the percentage of positive prostate biopsies in predicting prostate specific antigen (PSA) outcome after radical prostatectomy (RP) or external-beam radiation therapy (EBRT) for men with PSA-detected or palpable prostate cancer is not established. Methods: A Cox regression multivariable analysis was used to determine whether percent-positive prostate biopsies provided clinically relevant information about PSA outcome after RP in 960 men, while accounting for the previously established risk groups based on the pretreatment PSA concentration biopsy Gleason score, and the 1992 American Joint Commission on Cancer clinical T stage. Results: In the intermediate-risk group, 80% of the patients (stage T(2b) or biopsy Gleason 7 or PSA 10-20 ng/mL) could be classified into either an 11% or an 86% 4-year PSA control cohort using the preoperative prostate biopsy data. These findings were validated using an independent surgical (N = 823) and radiation (N = 473) data set. Percent-positive prostate biopsies added clinically significant information regarding time to PSA failure after RP. Conclusions: The percentage of positive prostate biopsies should be considered in conjunction with the PSA level, biopsy Gleason score, and clinical T stage when counseling patients with newly diagnosed and clinically localized prostate cancer about PSA outcome after RP or EBRT.

UR - http://www.scopus.com/inward/record.url?scp=0033762181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033762181&partnerID=8YFLogxK

M3 - Article

C2 - 11062371

AN - SCOPUS:0033762181

VL - 4

JO - Molecular Urology

JF - Molecular Urology

SN - 1091-5362

IS - 3

ER -